Document:

Exhibit 4.2

 

THIS WARRANT HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION
STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR SATISFACTORY ASSURANCES TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED WITH RESPECT TO SUCH SALE, OFFER, PLEDGE OR HYPOTHECATION.

 

WARRANT TO PURCHASE
COMMON STOCK

of

Relmada Therapeutics,
Inc. 

 

Void after September __, 2024

 

This certifies that, for value received,
                              , or registered assigns (“Holder”) is entitled, subject to the terms set forth below, to purchase from Relmada
Therapeutics, Inc. (the “Company”), a Nevada corporation, _________ shares of the Common Stock of the Company (the
“Shares”), upon surrender hereof, at the principal office of the Company referred to below and simultaneous
payment therefor in lawful money of the United States or otherwise as hereinafter provided, at the Exercise Price as set forth
in Section 2 below. This Warrant is issued pursuant to the Note and Warrant Purchase Agreements dated as of August __, 2017, among
the Company and certain Purchasers named therein (collectively, the “Purchase Agreement”). The number, character
and Exercise Price of such shares of Common Stock (the “Common Stock”) are subject to adjustment as provided
below. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange
therefor as provided herein.

 

1. Term
of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part,
during the term commencing September __, 2017 (the “Warrant Issue Date”), and ending at 5:00 p.m., Eastern
Time on the seventh anniversary of the Warrant Issue Date, and shall be void thereafter.

 

2. Exercise
Price. The Exercise Price per share of Common Stock at which this Warrant may be exercised shall be equal to $1.50
per share as adjusted from time to time pursuant to Section 10 below (the “Exercise Price”).

 

3. Exercise of Warrant.

 

(a) The
purchase rights represented by this Warrant are exercisable by the Holder in whole or in part at any time, or from time to time,
by the surrender of this Warrant and the Notice of Exercise annexed hereto duly completed and executed on behalf of the Holder,
at the office of the Company (or such other office or agency of the Company as it may designate by notice in writing to the Holder
at the address of the Holder appearing on the books of the Company), upon payment in cash or by check acceptable to the Company.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which
case, the Holder shall surrender this Warrant to the Company for cancellation within 3 Trading Days of the date the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number
of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. In the event of any dispute or discrepancy, the records
of the Company shall be controlling and determinative in the absence of manifest error. The Holder and any assignee, by acceptance
of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.

 

    	 	1	 

     

    

 

(b) This
Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its surrender for exercise
as provided above and payment of the Exercise Price if exercised for cash, and the person entitled to receive the shares of Common
Stock issuable upon such exercise shall be treated for all purposes as the holder of record of such shares as of the close of business
on such date (the “Exercise Date”). As promptly as practicable on or after the Exercise Date, but in no event
more than three (3) business days thereafter (the “Warrant Share Delivery Date”), the Company at its expense
shall issue and deliver to the person or persons entitled to receive the same a certificate or certificates for the number of shares
issuable upon such exercise. In the event that this Warrant is exercised in part, the Company at its expense will execute and deliver
a new Warrant of like tenor exercisable for the number of shares for which this Warrant may then be exercised.

 

4. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. In lieu of any fractional share to which the Holder would otherwise be entitled, the Company shall make a cash
payment equal to the Exercise Price multiplied by such fraction.

 

5. Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction, or mutilation
of this Warrant and, in the case of loss, theft, or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company
at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount.

 

6. Rights
of Shareholders. Until Holder exercises this Warrant and the Company issues Holder shares of Common Stock purchasable upon
the exercise hereof, as provided herein, Holder shall not be entitled to vote or receive dividends or be deemed the holder of Common
Stock or any other securities of the Company that may at any time be issuable on the exercise hereof for any purpose, nor shall
anything contained herein be construed to confer upon the Holder, as such, any of the rights of a shareholder of the Company or
any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give
or withhold consent or assert dissenter’s rights with respect to any corporate action (whether upon any recapitalization,
issuance of stock, reclassification of stock, change of par value, or change of stock to no par value, consolidation, merger, conveyance,
or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise.

 

7. Transfer of Warrant.

 

(a) Warrant
Register. The Company will maintain a register (the “Warrant Register”) containing the names and addresses
of the Holder or Holders. Any Holder of this Warrant or any portion thereof may change his address as shown on the Warrant Register
by written notice to the Company requesting such change. Any notice or written communication required or permitted to be given
to the Holder may be delivered or given by mail to such Holder as shown on the Warrant Register and at the address shown on the
Warrant Register. Until this Warrant is transferred on the Warrant Register of the Company, the Company may treat the Holder as
shown on the Warrant Register as the absolute owner of this Warrant for all purposes, notwithstanding any notice to the contrary.

 

    	 	2	 

     

    

 

(b) Warrant
Agent. The Company may, by written notice to the Holder, appoint an agent for the purpose of maintaining the Warrant Register
referred to in Section 7(a) above, issuing the Common Stock or other securities then issuable upon the exercise of this Warrant,
exchanging this Warrant, replacing this Warrant, or any or all of the foregoing. Thereafter, any such registration, issuance, exchange,
or replacement, as the case may be, shall be made at the office of such agent.

 

(c) Transferability
and Non-negotiability of Warrant. This Warrant may not be transferred or assigned in whole or in part without compliance with
the terms of this Warrant and all applicable federal and state securities laws by the transferor and the transferee (including
the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, if such are requested
by the Company).

 

(d) Compliance with Securities Laws.

 

(i) Holder
understands that the Warrant and the Shares are characterized as “restricted securities” under the 1933 Act inasmuch
as they are being acquired from the Company in a transaction not involving a public offering, and that under the Securities Act
of 1933, as amended (the “1933 Act”) and applicable regulations thereunder, such securities may be resold without
registration under the 1933 Act only in certain limited circumstances. In this connection, Holder represents that it is familiar
with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the 1933 Act. Holder understands
that the Company is under no obligation to register any of the securities sold hereunder except as provided in Section 11 hereof.
Holder understands that no public market now exists for any of the Warrants or the Shares and that it is uncertain whether a public
market will ever exist for the Warrants or the Shares.

 

(ii) This
Warrant and all certificates for the Shares issued upon exercise hereof shall be stamped or imprinted with a legend in substantially
the following form (in addition to any legend required by state securities laws):

 

“THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER SUCH ACT, (B) A “NO ACTION” LETTER OF THE SECURITIES
AND EXCHANGE COMMISSION WITH RESPECT TO SUCH SALE OR OFFER OR (C) SATISFACTORY ASSURANCES TO THE CORPORATION THAT REGISTRATION
UNDER SUCH ACT IS NOT REQUIRED WITH RESPECT TO SUCH SALE OR OFFER.”

 

    	 	3	 

     

    

 

(e) Disposition of Holder’s Rights.

 

(i) In
no event will the Holder make a disposition of any of its rights to acquire Shares under this Warrant and/or of any of the Shares
issuable upon exercise of any such rights unless and until (A) it shall have notified the Company of the proposed disposition,
(B) if requested by the Company, it shall have furnished the Company with an opinion of counsel (which counsel may either be inside
or outside counsel to the Holder) satisfactory to the Company and its counsel to the effect that (1) appropriate action necessary
for compliance with the 1933 Act has been taken, or (2) an exemption from the registration requirements of the 1933 Act is available,
and (C) if the disposition involves the sale of such rights or such Shares issuable upon exercise of such rights, it shall have
offered to the Company, pursuant to Section 7(f) hereunder, such rights to acquire Shares or Shares issuable and upon exercise
of such rights, as the case may be.

 

(ii) The restrictions
imposed under this Section 7(e) shall terminate as to any of the Shares when (A) such security shall have been effectively registered
under the 1933 Act and sold by the holder thereof in accordance with such registration or (B) such security may be sold without
registration in compliance with Rule 144 under the 1933 Act, or (C) a letter shall have been issued to the Holder at its request
by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the Holder at its request by such
Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security
is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and
such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder
shall terminate, as hereinabove provided, the Holder or holder of Shares then outstanding as to which such restrictions have terminated
shall be entitled to receive from the Company, without expense to such holder, one or more new certificates for the Warrant or
for such Shares not bearing any restrictive legend.

 

(h) Any entity
to whom Holder transfers any right to purchase the Shares pursuant to this Warrant or any of the Shares issuable upon the exercise
of such right shall become a “Holder” for purposes of this Section 7.

 

8. Reservation
of Stock. The Company covenants that during the term this Warrant is exercisable, the Company will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of Common Stock upon the exercise of this Warrant
and, from time to time, will take all steps necessary to amend its Fifth Amended and Restated Certificate of Incorporation (the
“Certificate”) as the same may be amended from time to time to provide sufficient reserves of shares of Common
Stock issuable upon exercise of the Warrant. The Company further covenants that all shares that may be issued upon the exercise
of rights represented by this Warrant, upon exercise of the rights represented by this Warrant and payment of the Exercise Price,
all as set forth herein, will be free from all taxes, liens, and charges in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously or otherwise specified herein). The Company agrees that its issuance of this Warrant
shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue
the necessary certificates for shares of Common Stock upon the exercise of this Warrant.

 

9. Amendments.

 

(a) This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder of this
Warrant.

 

(b) No
waivers of or exceptions to any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to
be, or construed as, a further or continuing waiver of any such term, condition or provision.

 

    	 	4	 

     

    

 

10. Adjustments.
The Exercise Price and the number of shares purchasable hereunder are subject to adjustment from time to time as follows:

 

(a) Reclassification.
In case of any reclassification, consolidation or merger of the Borrower with or into another entity or any merger of another entity
with or into the Borrower, or in the case of any sale, transfer or conveyance of all or substantially all of the assets of the
Borrower (computed on a consolidated basis), each Note then outstanding will, without the consent of any Holder, become convertible
only into the kind and amount of securities, cash or other property receivable upon such reclassification, consolidation, merger,
sale, transfer or conveyance by a Holder of the number of shares of Common Stock into which such Note was convertible immediately
prior thereto, after giving effect to any adjustment event.

 

(b)Stock Split,
Dividend. If the number of shares of Common Stock outstanding at any time after the date hereof is increased by a subdivision or
split of Common Stock, or by the declaration of a dividend on the Common Stock, which dividend is wholly or partially in the form
of additional shares of Common Stock or any other securities of the Borrower, then immediately after the effective date of such
subdivision or split-up, or the record date with respect to such dividend, as the case may be, the Exercise Price shall be appropriately
reduced so that the Holder of this Note thereafter exchanged shall be entitled to receive the percentage of shares of Common Stock
which such Holder would have owned immediately following such action had this Note been exchanged immediately prior thereto;

 

(c) Reverse
Split. If the number of Common Stock outstanding at any time after the date hereof is decreased by a combination of the outstanding
Common Stock or reverse split, then, immediately after the effective date of such combination, the Exercise Price shall be appropriately
increased so that the Holder of this Note thereafter exchanged shall be entitled to receive the percentage of shares of Common
Stock which such Holder would have owned immediately following such action had this Note been exchanged immediately prior thereto.

 

(b) Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 10, the Company at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of this Warrant
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based. The Company shall, upon the written request, at any time, of any such holder, furnish or cause to be furnished to such
holder a like certificate setting forth: (i) such adjustments and readjustments; (ii) the Exercise Price at the time in effect;
and (iii) the number of shares and the amount, if any, of other property which at the time would be received upon the exercise
of the Warrant.

 

    	 	5	 

     

    

 

11. Reclassification; Reorganization; Merger.

 

In case
of any capital reorganization, other than in the cases referred to in Section 10(a) hereof, or the consolidation or merger of the
Company with or into another corporation (other than a merger or consolidation in which the Company is the continuing corporation
and which does not result in any reclassification of the outstanding shares of Common Stock or the conversion of such outstanding
shares of Common Stock into shares of other stock or other securities or property), or in the case of any sale, lease, or conveyance
to another corporation of the property and assets of any nature of the Company as an entirety or substantially as an entirety (such
actions being hereinafter collectively referred to as “Reorganizations”), there shall thereafter be deliverable
upon exercise of this Warrant (in lieu of the number of Shares theretofore deliverable) the number of shares of stock or other
securities or property to which a holder of the respective number of Shares which would otherwise have been deliverable upon the
exercise of this Warrant would have been entitled upon such Reorganization if this Warrant had been exercised in full immediately
prior to such Reorganization. In case of any Reorganization, appropriate adjustment, as determined in good faith by the Board of
Directors of the Company, shall be made in the application of the provisions herein set forth with respect to the rights and interests
of the Holder so that the provisions set forth herein shall thereafter be applicable, as nearly as possible, in relation to any
shares or other property thereafter deliverable upon exercise of this Warrant. Any such adjustment shall be made by, and set forth
in, a supplemental agreement between the Company, or any successor thereto) and the Holder, with respect to this Warrant, and shall
for all purposes hereof conclusively be deemed to be an appropriate adjustment. The Company shall not effect any such Reorganization
unless, upon or prior to the consummation thereof, the successor corporation, or, if the Company shall be the surviving corporation
in any such Reorganization and is not the issuer of the shares of stock or other securities or property to be delivered to holders
of shares of the Common Stock outstanding at the effective time thereof then such issuer, shall assume by written instrument the
obligation to deliver to the Holder such shares of stock, securities, cash, or other property as such Holder shall be entitled
to purchase in accordance with the foregoing provisions. In the event of sale, lease, or conveyance or other transfer of all or
substantially all of the assets of the Company as part of a plan for liquidation of the Company, all rights to exercise this Warrant
shall terminate thirty (30) days after the Company gives written notice to the Holder that such sale or conveyance or other transfer
has been consummated.

 

The above
provisions of this Section 11 shall similarly apply to successive reclassifications and changes of shares of Common Stock and to
successive consolidations, mergers, sales, leases, or conveyances.

 

12 Miscellaneous.

 

(a) Additional
Undertaking. The Holder hereby agrees to take whatever additional action and execute whatever additional documents the Company
may deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on either
the Holder or the shares of Common Stock issued upon exercise hereof pursuant to the provisions of this Warrant.

 

(b) Governing
Law; Venue. This Warrant shall be governed by, and construed in accordance with, the laws of the State of Delaware without
resort to that State’s conflict-of-laws rules. Venue for any legal action hereunder shall be in the state or federal courts
located in the Borough of Manhattan, New York, New York.

 

(c) Counterparts.
This Warrant may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall
constitute one and the same instrument.

 

    	 	6	 

     

    

 

(d) Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors
and assigns and upon the Holder, the Holder’s permitted assigns and the legal representatives, heirs and legatees of the
Holder’s estate, whether or not any such person shall have become a party to this Warrant and have agreed in writing to join
herein and be bound by the terms hereof.

 

(e) Notices.
All notices, requests, demands and other communications given or made in accordance with the provisions of this Warrant shall be
addressed (i) if to Holder, at such Holder’s address, fax number or email address, as furnished to the Company on the signature
page to the Purchase Agreement or as otherwise furnished to the Company by the Holder in writing, or (ii) if to the Company, to
the attention of the President at such address, fax number or email address furnished to the Holder on the signature page to the
Purchase Agreement or as otherwise furnished by the Company in writing, and shall be made or sent by a personal delivery or overnight
courier, by registered, certified or first class mail, postage prepaid, or by facsimile or electronic mail with confirmation of
receipt, and shall be deemed to be given on the date of delivery when made by personal delivery or overnight courier, 48 hours
after being deposited in the U.S. mail, or upon confirmation of receipt when sent by facsimile or electronic mail. Any party may,
by written notice to the other, alter its address, number or respondent, and such notice shall be considered to have been given
three (3) days after the overnight delivery, airmailing, faxing or sending via e-mail thereof.

 

[Signatures appear on the following page]

 

    	 	7	 

     

    

 

IN WITNESS WHEREOF,
Relmada Therapeutics, Inc. has caused this Warrant to be executed by its officer thereunto duly authorized.

 

Dated as of September __, 2017.

 

 

	 	RELMADA THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	 	Sergio Traversa, PharmD
	 	 	Chief Executive Officer

 

    	 	8	 

     

    

 

NOTICE OF EXERCISE

 

To: Relmada Therapeutics, Inc.

 

		(1)	The undersigned hereby elects to purchase ____________________(_________) shares
of Common Stock of Relmada Therapeutics, Inc., pursuant to the terms of the attached Warrant, and tenders herewith payment
of the purchase price for such shares in full.

 

		(2)	Payment shall take the form of lawful money.

 

		(3)	In exercising this Warrant, the undersigned hereby confirms
and acknowledges that the shares of Common Stock have not been registered under the Securities Act of 1933, as amended (the “1933
Act”), and are restricted securities under the 1933 Act and that the undersigned will not offer, sell, or otherwise
dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the 1933 Act or any
state securities laws.

 

		(4)	Please issue a certificate or certificates representing
said shares of Common Stock in the name of the undersigned or in such other name as is specified below:

 

			Name _____________________________

 

		(5)	Please issue a new Warrant for the unexercised portion
of the attached Warrant in the name of the undersigned or in such other name as is specified below:

 

			Name______________________________

 

			Name______________________________

 

	Date:	 	 	Signature:  	 

 

 

9Exhibit 10.1

 

RELMADA THERAPEUTICS, INC.

 

NOTE AND WARRANT PURCHASE AGREEMENT

 

THIS NOTE AND WARRANT PURCHASE
AGREEMENT (the “Purchase Agreement”), dated this __ day of __________ 2017, is by and between ___________,
(the “Buyer”), and RELMADA, THERAPEUTICS, INC., a Nevada corporation (the “Company”).

 

WHEREAS, the Buyer
wishes to purchase from the Company and the Company wishes to sell to the Buyer, upon the terms and subject to the conditions of
this Purchase Agreement, a convertible promissory note of the Company, in the principal amount of $.

 

NOW THEREFORE, in consideration
of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:

 

1.Sale and Issuance of Note and
Warrant. Upon the terms and subject to the conditions of this Purchase Agreement, the Buyer agrees to purchase from the Company,
and the Company agrees to sell and issue to the Buyer, a convertible subordinated promissory note, in the form attached hereto
as Exhibit A (the “Note”), in the principal amount of $____________(the “Principal Sum”),
subject to the terms and conditions of the Note. In order to induce the Buyer to purchase the Note, the Company will deliver a
warrant, in the form attached hereto as Exhibit B (the “Warrant”), to the Buyer to purchase, subject
to the terms and conditions of the Warrant, in whole or in part, up to that number of fully paid, validly issued and nonassessable
shares of Company’s common stock (the “Common Stock”). Each Warrant will entitle such Investor to purchase up
to that number of shares of Common Stock equal to (a) fifty percent (50%) of the Principal Sum purchased by such Investor divided
by (b) $0.75. The exercise price per share for the Warrant shall be $1.50.

 

2. Representations and Warranties
of the Company. By executing this Purchase Agreement, the Company makes the following representations and, warranties to the
Buyer, with the intent and understanding that the Buyer will rely thereon:

 

2.1Organization of the Company; Authorization;
Good Standing. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State
of Nevada and has all requisite corporate power and authority to own and lease its property, to carry on its business as presently
conducted and as proposed to be conducted (as previously disclosed to the Buyer) and to execute and deliver, and to perform all
of its obligations under, this Purchase Agreement, the Note and the Warrant (collectively, the “Company Documents”).

 

2.2Enforceability.
The creation and issue of the Note and the execution and delivery by the Company of the Company Documents and the
consummation of the transactions contemplated thereby have been duly authorized by all requisite corporate action on the part
of the Company, and the Company Documents have been duly executed and delivered by the Company and constitutes the legal,
valid and binding obligation of the Company, enforceable in accordance with its terms.

 

2.3Complete
and Accurate Information. All information provided by the Company in whatever form in connection with the transactions
contemplated by the Company Documents are complete and accurate and provide a true and fair view of the financial position of
the Company.

 

    	 		 

     

    

 

3. Representations and Warranties
of the Buyer. By executing this Purchase Agreement, the Buyer makes the following representations and warranties to the Company,
with the intent and understanding that the Company will rely thereon:

 

3.1Investment Representations. The Buyer
has knowledge and experience in financial and business matters sufficient to enable him to evaluate the merits and risks of an
investment in the Note, the shares of the Company’s Common stock issuable upon conversion of the Note (the “Shares”)
and the Company. The Buyer has assets sufficient to enable him to bear the economic risk of the Buyer’s investment in the
Note. The Buyer is acquiring the Note for investment purposes only, for his, her or its own account, and not with a present view
to, or for sale in connection with, any distribution thereof. The Buyer understands that the Note and the Shares have not been
registered under the Securities Act by reason of their issuance in a transaction exempt from the registration requirements of
the Securities Act pursuant to the exemption provided in Section 4(2) thereof, that the Note and the Shares have not been registered
under applicable state securities laws by reason of their issuance in a transaction exempt from such registration requirements,
and that the Note and the Shares may not be sold or otherwise disposed of unless registered under the Securities Act and applicable
state securities laws (the Company being under no obligation to register such Note or the Shares) or exempted from registration.
The Buyer further acknowledges that the Note and the Shares are subject to the restrictions on transfers set forth in the Company
Documents, and that each transferee of the Note or the Shares as a condition to such transfer may be required to agree in writing
to be bound by such restrictions.

 

3.2Buyer’s Acknowledgment as to
Information. The Buyer or representatives of the Buyer have received from the Company such information (including
exhibits to this Purchase Agreement and of such documents referred to herein and therein as he or they have requested) with
respect to the Company as the Buyer has deemed necessary and relevant in connection with the transactions contemplated by the
Company Documents, and the Buyer has had the opportunity, directly or through such representatives, to ask questions of and
receive answers from persons acting on behalf of the Company necessary to verify the information so obtained.

 

3. Legend. Each certificate
evidencing the Note and the Company’s securities issuable upon conversion of the Note, and each certificate evidencing the
Note and the Company’s securities issuable upon conversion of the Note held by subsequent transferees of any such certificate,
shall be stamped or otherwise imprinted with a legend in substantially the following form:

 

"THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER SUCH ACT, (B) A "NO ACTION" LETTER OF THE SECURITIES
AND EXCHANGE COMMISSION WITH RESPECT TO SUCH SALE OR OFFER OR (C) SATISFACTORY ASSURANCES TO THE CORPORATION THAT REGISTRATION
UNDER SUCH ACT IS NOT REQUIRED WITH RESPECT TO SUCH SALE OR OFFER."

 

    	 	2	 

     

    

 

4. Miscellaneous.

 

4.1 Legal
Fees and Expenses. Each party hereto agrees to pay its own legal fees and expenses incurred in connection with the
transactions contemplated hereunder.

 

4.2 No
Waiver. The failure of a party to insist upon strict adherence to any term of this Purchase Agreement on any occasion shall
not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other
term of this Purchase Agreement. Any waiver of any term of this Purchase Agreement must be in writing.

 

4.3 Entire
Agreement; Amendment. This Purchase Agreement and all Exhibits hereto, set forth the entire agreement of the parties with
respect to the subject matter hereof and supersede all prior agreements relating thereto, written or oral. This Purchase
Agreement may be amended or modified only by a written instrument executed by the Company and the Buyer.

 

4.4 Parties
in Interest; Limitation on Assignment. This Purchase Agreement shall inure to the benefit of and be binding upon the
parties and their respective permitted successors and assigns.

 

4.5 Counterparts.
This Purchase Agreement may be executed in any number of counterparts, each of which shall be considered an original, but all
of which together shall constitute one and the same instrument.

 

4.6 Governing
Law. This Purchase Agreement shall be governed by, construed, interpreted and enforced in accordance with the laws of the
State of New York as applied to contracts entered into and performed entirely within the State of New York without regard to
conflicts of laws principles.

 

4.7 Notices.
All notices, consents and other communications under this Purchase Agreement shall be in writing and shall be deemed to have
been duly given when (a) delivered by hand, (b) sent by telex or telecopier (with receipt confirmed), provided that a copy is
mailed by registered mail, return receipt requested, or (c) when received by the addressee, if sent by Express Mail, Federal
Express or other express delivery service (receipt requested), in each case to the appropriate addresses, telex numbers and
telecopier numbers set forth below (or to such other addresses, telex numbers and telecopier numbers as a party may designate
as to itself by notice to the other party):

 

4.7.1 If to the Company:

 

RELMADA THERAPEUTICS, INC.

750 Third Avenue, 9th floor

New York, NY 10017

Attention: Sergio Traversa, PharmD.

Chief Executive Officer

 

    	 	3	 

     

    

 

4.7.2 If to the Buyer:

 

 

 

 

4.8Severability. In the event that
any court having jurisdiction shall determine that any provision contained in this Purchase Agreement shall be unreasonable
or unenforceable in any respect, then such covenant or other provision shall be deemed limited to the extent that such court
deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that such court
shall deem any such covenant or other provision wholly unenforceable, the remaining covenants and other provisions of this
Purchase Agreement shall nevertheless remain in full force and effect.

 

4.9Headings and Captions. The
headings and captions used herein to identify sections and subsections are for convenience only and shall not be used for
interpretation of any provisions herein.

 

4.10 Indemnity. The
representations, warranties and agreements made by the Company and the Buyer herein shall survive the execution of this
Purchase Agreement. The Company and the Buyer hereby agree to indemnify and hold harmless the other party from and
against any and all loss, liability, claim, damage and expense (including, without limitation, attorneys’ fees and
disbursements) suffered or incurred as a result of a misrepresentation or breach of any warranty or agreement made by the
defaulting party in this Purchase Agreement.

 

[Signature Page Follows]

 

    	 	4	 

     

    

 

IN WITNESS
WHEREOF, each of the parties has caused this Purchase Agreement to be executed on its behalf with the intent to be legally
bound as of the day and year first above written.

 

	 	 	 	RELMADA THERAPEUTICS, INC.
	 	 	 	 
	 	 	 	By: 	          
	 	 	 	Name:	Sergio Traversa, PharmD
	 	 	 	Title: 	Chief Executive Officer
	 	 	 	 	 
	BUYER:	 	 	 
	 	 	 	 	 
	     	 	 	 
	Name:	 	 	 	 
	Title:	 	 	 	 

 

    	 		 

     

    

 

EXHIBIT A

 

FORM OF CONVERTIBLE PROMISSORY NOTE

 

(see attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]